Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response.
The prognostic importance of baseline urines for cocaine was examined in a randomized, placebo-controlled, twelve-week clinical trial in 165 opioid- and cocaine-dependent patients who were treated with desipramine (DMI) in combination with buprenorphine (BUP) or methadone (Meth). Patients with a cocaine-positive urine at baseline (CU+) had significantly fewer cocaine-free urines than those with a negative urine at baseline (CU-neg). The CU+ patients showed a treatment effect of DMI. This DMI effect was significant in patients maintained on BUP but not on Meth.
Kosten
Thomas
T
Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, CT 06516, USA. Thomas.Kosten@yale.edu
Sofuoglu
Mehmet
M
Poling
James
J
Gonsai
Kishor
K
Oliveto
Alison
A
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D002047:Buprenorphine / Q000627:therapeutic use; D003042:Cocaine / Q000652:urine*; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation*; D003891:Desipramine / Q000627:therapeutic use*; D018765:Dopamine Uptake Inhibitors / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D008875:Middle Aged; D009292:Narcotic Antagonists / Q000627:therapeutic use; D010919:Placebos; D011237:Predictive Value of Tests; D011379:Prognosis; D016896:Treatment Outcome; D016482:Urinalysis
D018759:Adrenergic Uptake Inhibitors; D018765:Dopamine Uptake Inhibitors; D009292:Narcotic Antagonists; D010919:Placebos; D002047:Buprenorphine; D003042:Cocaine; D003891:Desipramine; D008691:Methadone